Pacira Pharmaceuticals buy Truist Financial Co.
Start price
25.07.24
/
50%
€18.40
Target price
25.07.25
€27.62
Performance (%)
2.17%
End price
26.07.25
€18.80
Summary
This prediction ended on 26.07.25 with a price of €18.80. With a performance of 2.17%, the BUY prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals closed with a slight gain. Truist_Financial_Co_ has a follow-up prediction for Pacira Pharmaceuticals where he still thinks Pacira Pharmaceuticals is a Buy. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pacira Pharmaceuticals | -4.369% | -4.369% | 40.714% |
| iShares Core DAX® | 0.641% | 3.579% | 27.134% |
| iShares Nasdaq 100 | 2.167% | 6.631% | 17.570% |
| iShares Nikkei 225® | 4.902% | 9.562% | 13.355% |
| iShares S&P 500 | 1.672% | 4.814% | 11.218% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Truist Financial Co. from $45.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
In the thread Trading Pacira Pharmaceuticals
Die von Truist_Financial_Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.90
25.07.25
25.07.25
€25.55
25.07.26
25.07.26
5.82%
07:31
07:31
